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medication; “appropriate therapy”) and CHBNAi (CUs not
using any anti-inﬂammatory medication). Univariate analyses for
continuous variables was performed using Mann-Whitney U test;
and multivariate logistic regression was performed to predict the
probability of being on appropriate therapy. RESULTS: A total
of 1127 chronic users were identiﬁed (474 before and 653 after
the introduction of the guidelines). A higher proportion of
CHBYAi patients were found after the introduction of the guide-
lines (7%, Chi-square test, p-value = 0.041). However, both
before and after the introduction of the guidelines the CHBNAi
had signiﬁcantly fewer asthma-related total (physician, ER and
hospital) visits and costs (all p-value = 0.000). Multivariate logis-
tic regression results indicated that total asthma-related visits
was signiﬁcantly associated with the odds of being on appropri-
ate therapy. Before the guidelines, for every asthma related visit
the odds of being on appropriate guidelines was found to be
1.544 (95% CI: 1.327–1.797); for every asthma related visit the
odds of being on appropriate therapy was found to be 1.937
(95%CI: 1.624–2.309). CONCLUSION: We would have
expected a higher health care utilization (visits & cost) for the
CHBNAi group but we could not conclude this.
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Previous studies have shown that costs for asthma care tend to
be higher among recipients of Medicaid compared to patients
covered by private insurance. OBJECTIVE: Report the costs for
asthma-related health care in a state Medicaid Program.
METHODS: Medicaid medical services claims with a primary
ICD-9 diagnosis code for asthma dated 2002 were extracted.
Matching claims for asthma-related prescription medications
also were collected. Costs for outpatient visits, emergency
department (ED) visits, and prescriptions were based on dollars
reimbursed by Medicaid. Costs for hospitalizations were esti-
mated based on average DRG reimbursements. RESULTS: There
were 16,573 recipients with claims for asthma. Among demo-
graphic groups, a majority of recipients were younger than 15
years (44%), female (58%), and white (93%). Medicaid paid
roughly $12.9 million for asthma-related medical services and
prescriptions, or an average of $779 per recipient with asthma.
A majority of the dollars were paid for services and prescriptions
utilized by adults between 21 and 64 years of age (49%), females
(61%), and caucasians (93%). Hospitalization costs amounted
to $3.5 million (27% of the total) at an average cost of nearly
$4000 per admission. ED costs equaled over $619,000 (5% of
the total) at an average cost of $169 per visit. Outpatient costs
were nearly $2.4 million (19% of the total) at an average cost
of $83 per visit. Prescription costs totaled $6.2 million (48% of
the total) for an average cost of $51 per prescription. A major-
ity of the dollars paid for prescriptions were for leukotriene mod-
iﬁers (33%), short-acting beta-agonists (23%), and inhaled
corticosteroids (21%). CONCLUSIONS: Asthma is responsible
for a substantial consumption of economic resources of the Med-
icaid Program. Roughly half of the dollars Medicaid spends for
asthma care is for medical services and half for prescription
drugs. Hospitalizations account for a majority of medical ser-
vices costs.
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OBJECTIVES: This study evaluates the effect of over-the-
counter (OTC) availability of loratadine on utilization and
spending in a state Medicaid population without OTC coverage.
Using a subset of nearly 100,000 enrollees before and after
loratadine OTC availability, the speciﬁc objectives of this study
were to: 1) evaluate product switching behavior; 2) describe non-
sedating antihistamine utilization patterns; and 3) describe non-
sedating antihistamine expenditures and their response to OTC
availability. METHODS: The study was conducted retrospec-
tively using paid pharmacy claims for a subset of Medicaid 
beneﬁciaries. Non-sedating antihistamine use was evaluated for
two 12 month intervals encompassing July 1, 2001 through June
30, 2003. Within each interval, the rate of product switching
between the ﬁrst 5 months and last 5 months was evaluated.
Trends in utilization and spending were tracked for the entire
24-month period. RESULTS: Beneﬁciaries using loratadine in the
OTC availability interval were 2.4 (95% CI; 2.08–2.41) times
more likely to switch to a different non-sedating antihistamine
and 1.09 (95% CI: 1.08–1.12) times more likely to not have a
non-sedating antihistamine claim than beneﬁciaries in the non-
OTC availability interval. The largest gain in market share was
observed for cetirizine, although desloratadine accounted for the
largest switch rate from loratadine. During the ﬁrst 12 months
of the study, non-sedating antihistamine expenditures increased
by nearly $28,000 per month. Despite availability of a less costly
alternative, expenditures increased by $13,000 per month during
the last 12 months. CONCLUSIONS: Although utilization and
spending tapered slightly after the introduction of loratadine
OTC, the majority of beneﬁciaries using loratadine switched to
a covered alternative once the OTC product was on the market.
Given the potential cost-savings associated with OTC loratadine
(compared to the prescription only competitors) and the high
likelihood of switching, it appears that state Medicaid programs
should consider coverage of both prescription and OTC 
products.
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OBJECTIVE: To identify patient behaviors that affect adherence
regarding asthma and its management using Q-methodology.
New insight into patient attitudes may facilitate further devel-
opment of interventions, which remove barriers affecting adher-
ence in asthma. While many theoretical frames have been
proposed, this is the ﬁrst application of Q-methodology to this
problem. METHODS: A literature search, and interviews with
clinicians and patients were used to create a concourse of reasons
for non-adherence in asthma. The raw set of ideas in the con-
course were deﬁned, clariﬁed and combined into more mean-
